Clinical Impact of Gastric Acid-Suppressing Medication Use on the Efficacy of Erlotinib and Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations.
作者:
主题词
成年人(Adult);老年人(Aged);老年人, 80以上(Aged, 80 and over);抗肿瘤药(Antineoplastic Agents);癌, 非小细胞肺(Carcinoma, Non-Small-Cell Lung);无病生存(Disease-Free Survival);女(雌)性(Female);胃酸(Gastric Acid);组胺H2拮抗剂(Histamine H2 Antagonists);人类(Humans);肺肿瘤(Lung Neoplasms);男(雄)性(Male);中年人(Middle Aged);突变(Mutation);蛋白激酶抑制剂(Protein Kinase Inhibitors);质子泵抑制剂(Proton Pump Inhibitors);喹唑啉类(Quinazolines);回顾性研究(Retrospective Studies);治疗结果(Treatment Outcome)
DOI
10.1016/j.cllc.2016.01.006
PMID
26944770
发布时间
2018-12-02
- 浏览13

Clinical lung cancer
412-418页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文